Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Effect of dendritic cells (DC) transduced with chimeric antigen receptor (CAR) on CAR T-cell cytotoxicity.
Authors
Hyung Chan Suh
Regents of the University of California, Los Angeles, Los Angeles, CA
Hyung Chan Suh, Katherine Pohl, Anna Patricia L. Javier, Dennis J. Slamon, John P Chute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Adoptive T-cell therapy: Modified and Unmodified Cells
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 144)
DOI
10.1200/JCO.2017.35.7_suppl.144
Abstract #
144
Poster Bd #
G3
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Eradication of medulloblastoma by NKG2D-specific CAR T-cells.
First Author: Hong-jiu Dai
Poster
2015 ASCO Annual Meeting
MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells.
First Author: Aaron E Foster
Poster
2024 ASCO Annual Meeting
Preclinical assessment of IPH6501, a first-in-class IL2v-armed tetraspecific NK cell engager directed against CD20 for R/R B-NHL, in comparison with a CD20-targeting T cell engager.
First Author: Olivier Demaria
Poster
2022 ASCO Annual Meeting
In-vivo reprogramming macrophages and dendritic cells with Allocetra-OTS: Successful mono- and combination-antitumor therapy.
First Author: Dror Mevorach